相关实验视频

Updated: Feb 24, 2026

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

复合性肉毒毒素A型对中度至重度骨线的安全性和有效性:一个多中心随机对照试验

Qingfeng Li¹, Xiao Long², Chongyuan Xu³

¹Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 639 Zhizaoju Road, Shanghai, China.

Plastic and reconstructive surgery

|February 23, 2026

概括

第一个重组性肉毒毒素A型 (rBoNT/A),YY001,在一期试验中显示出安全且耐受性良好的概况,用于 glabellar 线. 效率随着剂量增加而增加,这表明治疗纹的潜力.

科学领域:

生物化学生物化学
药理学药理学是指药理学的学科.
毒理学毒理学毒理学

背景情况:

YY001 (Retoxin®) 是第一个在人类中测试的复合性肉毒毒素A型 (rBoNT/A) 药物.
它含有纯粹的150kDa核心神经毒素,与天然的BoNT/A (nBoNT/A) 完全相同.

研究的目的:

评估YY001在人类中的安全性和初步疗效.
评估YY001用于治疗中度至重度的皮纹.

主要方法:

一期,多中心,双盲,随机,剂量范围的试验.
50名参与者接受了YY001 (10,20,30U),Botox® (20U) 或车辆.
主要终点:28天内的不良事件;次要:疗效评估.

主要成果:

对YY001 (10-30U) 没有观察到与药物相关的不良事件.
在第28天的反应率为60% (10U YY001),80% (20U YY001),90% (30U YY001),70% (20U Botox®).
没有/轻度皮纹的比例:80% (10 U YY001),90% (20 U YY001),100% (30 U YY001),80% (20 U Botox®) 没有/轻度皮纹.

结论:

第一个rBoNT/A (YY001) 在中国试验对象中显示出良好的安全性和耐受性.
YY001显示了对中度至严重的 glabellar 线的剂量依赖疗效.
良好的安全性概况与剂量无关.

关键词:

有效性有效性.中度至重度的皮线.复合肉毒毒素A型复合肉毒素A型复合肉毒素安全的安全的安全的安全的安全.在YY001中,YY001是指YY001,YY001是指YY001.

更多相关视频

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Published on: March 3, 2014

A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors

A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors

Published on: November 14, 2014

相关概念视频

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...

Peripherally and Centrally Acting Muscle Relaxants: A Comparison

Peripherally and Centrally Acting Muscle Relaxants: A Comparison

Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...